메뉴 건너뛰기
Gynecologic Oncology
Volumn 131, Issue 3, 2013, Pages 567-573
Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study
Author keywords

Platinum sensitivity; Platinum based chemotherapy; Recurrent endometrial cancer; Second line chemotherapy
Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; NEDAPLATIN; PACLITAXEL;
EID: 84888285940     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.09.021     Document Type: Article
Times cited : (67)
References (9)
  • 1
    • 0024522049 scopus 로고
    • Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design of phase II trials
    • G. Blackledge, F. Lawton, and C. Redman Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials Br J Cancer 59 1989 650 653
    • (1989) Br J Cancer , vol.59 , pp. 650-653
    • Blackledge, G.1    Lawton, F.2    Redman, C.3
  • 2
    • 0026086870 scopus 로고
    • Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin
    • M. Markman, R. Rothman, T. Hakes, B. Rechman, W. Hoskins, and S. Rubin Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J Clin Oncol 9 1991 389 393
    • (1991) J Clin Oncol , vol.9 , pp. 389-393
    • Markman, M.1    Rothman, R.2    Hakes, T.3    Rechman, B.4    Hoskins, W.5    Rubin, S.6
  • 3
    • 33644836069 scopus 로고    scopus 로고
    • Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group study
    • M.E. Randall, V.L. Filiaci, H. Muss, N.M. Spirtos, R.S. Mannel, and J. Fowler Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study J Clin Oncol 24 2006 36 44
    • (2006) J Clin Oncol , vol.24 , pp. 36-44
    • Randall, M.E.1    Filiaci, V.L.2    Muss, H.3    Spirtos, N.M.4    Mannel, R.S.5    Fowler, J.6
  • 4
    • 37349026899 scopus 로고    scopus 로고
    • Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate-and high risk endometrial cancer: A Japanese Gynecologic Oncology Group study
    • N. Susumu, S. Sagae, Y. Udagawa, K. Niwa, H. Kuramoto, and S. Satoh Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate-and high risk endometrial cancer: a Japanese Gynecologic Oncology Group study Gynecol Oncol 108 2008 226 233
    • (2008) Gynecol Oncol , vol.108 , pp. 226-233
    • Susumu, N.1    Sagae, S.2    Udagawa, Y.3    Niwa, K.4    Kuramoto, H.5    Satoh, S.6
  • 5
    • 35649019787 scopus 로고    scopus 로고
    • Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration
    • J.P. Vandenvbroucke, E. von Elm, D.G. Altman, P.C. Gotzsche, C.D. Mulrow, and S.J. Pocock Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration PLoS Med 4 10 2007 e297
    • (2007) PLoS Med , vol.4 , Issue.10 , pp. 297
    • Vandenvbroucke, J.P.1    Von Elm, E.2    Altman, D.G.3    Gotzsche, P.C.4    Mulrow, C.D.5    Pocock, S.J.6
  • 6
    • 78649559263 scopus 로고    scopus 로고
    • Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?
    • K.N. Moore, C. Tian, D.S. McMeekin, J.T. Tigpen, M.E. Randall, and H.H. Gallion Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer? Cancer 116 2010 5407 5414
    • (2010) Cancer , vol.116 , pp. 5407-5414
    • Moore, K.N.1    Tian, C.2    McMeekin, D.S.3    Tigpen, J.T.4    Randall, M.E.5    Gallion, H.H.6
  • 7
    • 70350569304 scopus 로고    scopus 로고
    • Practice pattern for postoperative management of endometrial cancer in Japan: A survey of the Japanese Gynecologic Oncology Group
    • Y. Watanabe, R. Kitagawa, D. Aoki, S. Takeuchi, S. Sagae, and N. Sakuragi Practice pattern for postoperative management of endometrial cancer in Japan: a survey of the Japanese Gynecologic Oncology Group Gynecol Oncol 115 2009 456 459
    • (2009) Gynecol Oncol , vol.115 , pp. 456-459
    • Watanabe, Y.1    Kitagawa, R.2    Aoki, D.3    Takeuchi, S.4    Sagae, S.5    Sakuragi, N.6
  • 8
    • 79954427920 scopus 로고    scopus 로고
    • Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin
    • Y. Ueda, T. Miyake, T. Egawa-Takata, S. Matsuzaki, T. Yokoyama, and Y. Miyoshi Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin Cancer Chemother Pharmacol 67 2011 829 835
    • (2011) Cancer Chemother Pharmacol , vol.67 , pp. 829-835
    • Ueda, Y.1    Miyake, T.2    Egawa-Takata, T.3    Matsuzaki, S.4    Yokoyama, T.5    Miyoshi, Y.6
  • 9
    • 78651060615 scopus 로고    scopus 로고
    • Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition
    • S. Nagase, H. Katabuchi, M. Hiura, N. Sakuragi, Y. Aoki, and J. Kigawa Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition Int J Clin Oncol 15 2010 531 542
    • (2010) Int J Clin Oncol , vol.15 , pp. 531-542
    • Nagase, S.1    Katabuchi, H.2    Hiura, M.3    Sakuragi, N.4    Aoki, Y.5    Kigawa, J.6

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.